153 related articles for article (PubMed ID: 3261863)
21. A p53 defect sensitizes various stages of B cell development to lymphomagenesis in mice carrying an IgH 3' regulatory region-driven c-myc transgene.
Fiancette R; Rouaud P; Vincent-Fabert C; Laffleur B; Magnone V; Cogné M; Denizot Y
J Immunol; 2011 Dec; 187(11):5772-82. PubMed ID: 22039300
[TBL] [Abstract][Full Text] [Related]
22. MHC class I expression on prelymphomatous and lymphomatous B-cells is not inhibited by an E mu-myc transgene.
Algarra I; Silva S; Ljunggren HG
Eur J Cancer; 1993; 29A(2):238-41. PubMed ID: 8422288
[TBL] [Abstract][Full Text] [Related]
23. The myc oncogene and lymphoid neoplasia: from translocations to transgenic mice.
Cory S; Harris AW; Langdon WY; Alexander WS; Corcoran LM; Palmiter RD; Pinkert CA; Brinster RL; Adams JM
Haematol Blood Transfus; 1987; 31():248-51. PubMed ID: 3502109
[No Abstract] [Full Text] [Related]
24. B-cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc translocus is independent of the heavy chain intron enhancer (Emu).
Palomo C; Zou X; Nicholson IC; Bützler C; Brüggemann M
Cancer Res; 1999 Nov; 59(21):5625-8. PubMed ID: 10554044
[TBL] [Abstract][Full Text] [Related]
25. Rearrangement of the c-myc oncogene with heavy-chain immunoglobulin enhancer in tumor DNA from an acute lymphoblastic leukemia patient.
Guerrasio A; Avanzi GC; Pegoraro L; Estivill X; Serra A; Giubellino MC; Fierro MT; Novarino A; Foa R; Saglio G
J Natl Cancer Inst; 1987 May; 78(5):845-51. PubMed ID: 3106693
[TBL] [Abstract][Full Text] [Related]
26. Cell populations during tumorigenesis in Eu-myc transgenic mice.
Sidman CL; Shaffer DJ; Jacobsen K; Vargas SR; Osmond DG
Leukemia; 1993 Jun; 7(6):887-95. PubMed ID: 8501983
[TBL] [Abstract][Full Text] [Related]
27. Growth of E mu-myc transgenic B-lymphoid cells in vitro and their evolution toward autonomy.
Langdon WY; Harris AW; Cory S
Oncogene Res; 1988; 3(3):271-9. PubMed ID: 3144697
[TBL] [Abstract][Full Text] [Related]
28. Surface IgM mediated regulation of RAG gene expression in E mu-N-myc B cell lines.
Ma A; Fisher P; Dildrop R; Oltz E; Rathbun G; Achacoso P; Stall A; Alt FW
EMBO J; 1992 Jul; 11(7):2727-34. PubMed ID: 1628630
[TBL] [Abstract][Full Text] [Related]
29. Lymphoid neoplasia and the control of haemopoietic differentiation.
Adams JM; Harris AW; Langdon WY; Klinken SP; Kongsuwan K; Alexander WS; Hariharan I; Vaux D; Rosenbaum H; Crawford M
Ciba Found Symp; 1989; 142():54-64; discussion 65-70. PubMed ID: 2568245
[TBL] [Abstract][Full Text] [Related]
30. Lymphomagenesis in E mu-myc transgenic mice can involve ras mutations.
Alexander WS; Bernard O; Cory S; Adams JM
Oncogene; 1989 May; 4(5):575-81. PubMed ID: 2657573
[TBL] [Abstract][Full Text] [Related]
31. Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors.
Sheppard RD; Samant SA; Rosenberg M; Silver LM; Cole MD
Oncogene; 1998 Oct; 17(16):2073-85. PubMed ID: 9798678
[TBL] [Abstract][Full Text] [Related]
32. Transgenic mice as a means to study synergism between oncogenes.
Berns A; Breuer M; Verbeek S; van Lohuizen M
Int J Cancer Suppl; 1989; 4():22-5. PubMed ID: 2681009
[TBL] [Abstract][Full Text] [Related]
33. In a model of immunoglobulin heavy-chain (IGH)/MYC translocation, the Igh 3' regulatory region induces MYC expression at the immature stage of B cell development.
Yan Y; Park SS; Janz S; Eckhardt LA
Genes Chromosomes Cancer; 2007 Oct; 46(10):950-9. PubMed ID: 17639584
[TBL] [Abstract][Full Text] [Related]
34. Immunologic competence of B cells subjected to constitutive c-myc oncogene expression in immunoglobulin heavy chain enhancer myc transgenic mice.
Vaux DL; Adams JM; Alexander WS; Pike BL
J Immunol; 1987 Dec; 139(11):3854-60. PubMed ID: 2445821
[TBL] [Abstract][Full Text] [Related]
35. Transformation of bone marrow cells from E mu-myc transgenic mice by Abelson murine leukemia virus and Harvey murine sarcoma virus.
Dyall-Smith D; Cory S
Oncogene Res; 1988 May; 2(4):403-9. PubMed ID: 2840624
[TBL] [Abstract][Full Text] [Related]
36. Transgenic rabbits with lymphocytic leukemia induced by the c-myc oncogene fused with the immunoglobulin heavy chain enhancer.
Knight KL; Spieker-Polet H; Kazdin DS; Oi VT
Proc Natl Acad Sci U S A; 1988 May; 85(9):3130-4. PubMed ID: 2834733
[TBL] [Abstract][Full Text] [Related]
37. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
38. Growth- and tumor-promoting effects of deregulated BCL2 in human B-lymphoblastoid cells.
Nunez G; Seto M; Seremetis S; Ferrero D; Grignani F; Korsmeyer SJ; Dalla-Favera R
Proc Natl Acad Sci U S A; 1989 Jun; 86(12):4589-93. PubMed ID: 2543982
[TBL] [Abstract][Full Text] [Related]
39. The VpreB1 enhancer drives developmental stage-specific gene expression in vivo.
Licence S; Persson C; Mundt C; Mårtensson IL
Eur J Immunol; 2003 Apr; 33(4):1117-26. PubMed ID: 12672078
[TBL] [Abstract][Full Text] [Related]
40. Targeted overexpression of an activated N-ras gene results in B-cell and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia.
Linden MA; Kirchhof N; Carlson CS; Van Ness BG
Exp Hematol; 2012 Mar; 40(3):216-27. PubMed ID: 22120021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
